Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2015

View Archived Issues

Anika Therapeutics forms strategic collaboration with the Institute for Applied Life Sciences

Vect-Horus establishes scientific collaboration with Servier

OWC Pharmaceutical Research presents lab results on CBD/THC combinations for multiple myeloma

AstraZeneca announces two collaborations in diabetes and chronic kidney disease

IRICoR and CCRM partner to launch spin off ExCellThera

GSK to create independent research institute

ARCA biopharma closes private placement financing round

Pembrolizumab receives U.S. orphan drug status for gastric cancer

Phase I protocol presented for a recessive dystrophic epidermolysis bullosa gene therapy

Radiolabeled chemokine receptor-targeting peptides as inflammation tracers

Radioiodinated therapeutic monoclonal antibody developed as an oncological tracer

GALGT2 gene therapy named FDA orphan drug for Duchenne muscular dystrophy

TapImmune gains additional funding

Mutations identified in three retinal dystrophy genes related o retinitis pigmentosa

Emulate deploys Organs-on-Chips platform across Janssen programs

Kyoto University describes new NK-3R agonists

Laboratorio Farmaceutico CT patents gamma-hydroxybutyric acid prodrugs

Canbex Therapeutics develops CB1 receptor agonists

Results of phase III study of biosimilar infliximab in patients with rheumatoid arthritis

Pfizer divulges JAK3 inhibitors

UCLB reports development of HIF-1alpha inhibitors

European Commission approves Opdivo for advanced melanoma

FDA approves Fycompa as adjunctive treatment for primary generalized tonic-clonic seizures

ReNeuron and Benitec extend research collaboration

Global ALS Day: New avenues in research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...